サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1363106

核酸医薬CDMOの市場規模、シェア、動向分析レポート：タイプ別、サービス別、エンドユーザー別、用途別、地域別、セグメント別予測、2023年～2030年

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service (Process Development & Optimization, Manufacturing Services), By End-user, By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
核酸医薬CDMOの市場規模、シェア、動向分析レポート：タイプ別、サービス別、エンドユーザー別、用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月21日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

核酸医薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の核酸医薬CDMO市場規模は、2023年から2030年までCAGR 9.4%で推移し、2030年までに224億2,000万米ドルに達する見込みです。

同市場の成長は主に、核酸医薬に対する需要の増加、核酸技術の進歩、核酸医薬のFDA承認の増加といった要因が、費用対効果の高い受託開発・製造サービスのニーズを後押ししていることに起因しています。

バイオテクノロジー企業、製薬会社、学術機関による遺伝子治療研究開発への投資と関心の高まりが、CDMOサービスの需要を促進しています。CDMOは遺伝子治療製造において重要な役割を果たしています。例えば、キャタレント社はサレプタ・セラピューティクス社の商業製造パートナーとして、遺伝子治療ソリューションを推進するための主要な役割を担っています。

COVID-19パンデミックへの対応におけるmRNAワクチンの成功は、核酸医薬の可能性を示し、この分野でのさらなる研究と投資を刺激しました。例えば、サノフィは2022年3月、フランスにおけるメッセンジャーRNAワクチンの開発に今後数年間で10億2,000万米ドル（9億3,500万ユーロ）を充てる予定であると発表しました。サノフィは、2021年6月に発表した20億ユーロ規模の世界投資イニシアチブの一環として、2026年までこの投資を行う予定です。このイニシアチブは、同社のmRNA戦略を促進するためのものです。このような資金増加シナリオは市場成長を促進します。

さらに、CDMOの買収や提携の増加は、今後数年間、核酸医薬CDMOの市場成長を加速させると予想されます。例えば、2022年5月、eureKAREは細胞・遺伝子治療受託開発製造機関（CDMO）を設立するため、1億6,098万米ドル（1億5,000万ユーロ）相当の合併を開始しました。

同社は、欧州の3つの開発・製造受託機関（CDMO）を統合する目的で、特別目的買収会社（SPAC）であるeureKINGを設立しました。また、富士フイルムは2022年4月、カリフォルニア州にあるAtara Biotherapeutics, Inc.から細胞治療に特化した製造施設を取得することで、先端治療薬の開発・製造受託機関（CDMO）のポートフォリオを拡大しました。このような取り組みが市場の成長を後押しすると期待されています。

核酸医薬CDMO市場レポートハイライト

  • RNAベースの治療薬セグメントが2022年に最大の収益シェアを占めました。RNAベースの治療薬（主にmRNA）は、様々な疾患への対応において汎用性があります。さまざまな治療用タンパク質を産生するように設計できるため、多様な治療領域に応用できます。
  • 遺伝子治療分野は、今後数年間で大きな市場成長が見込まれます。これは、遺伝子治療の臨床的成功が、遺伝子治療の適応拡大に役立っているためです。
  • 2022年には、製造サービス分野が市場を独占し、総収益シェアの38％以上を占めました。同分野の成長に寄与する主な課題には、複雑な製造プロセス、スケールアップと生産の課題、コスト効率などがあります。
  • バイオテクノロジー企業は、革新的な治療法の研究開発に多額の投資を行っているため、2022年には58%以上の主要収益シェアを占めました。
  • 用途別では、がん領域が2022年に31.0%を超える収益シェアを獲得して世界市場をリードしました。この背景には、遺伝子治療やRNAベースの治療薬の採用が増加していることや、がん領域向けの核酸医薬のパイプラインが増加していることがあります。
  • 2022年の核酸治療CDMO市場では、北米が38.49%の最大収益シェアを占めました。多額の投資と資金援助、強力な学術・研究機関、CDMOの世界の拡大がこの地域の成長を牽引しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場動向と展望
  • 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析
    • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 タイプ別ビジネス分析

  • 核酸医薬CDMO市場：タイプ変動分析
  • 遺伝子治療
  • RNAベースの治療

第5章 サービス別ビジネス分析

  • 核酸医薬CDMO市場：サービス変動分析
  • プロセスの開発と最適化
  • 製造サービス
  • 分析および品質管理サービス
  • その他

第6章 エンドユーザー別ビジネス分析

  • 核酸医薬CDMO市場：エンドユーザーの変動分析
  • 製薬会社
  • 政府および学術調査機関
  • バイオテクノロジー企業

第7章 用途別ビジネス分析

  • 核酸医薬CDMO市場：用途変動分析
  • オンコロジー
  • 遺伝性疾患
  • 感染症
  • その他

第8章 地域別ビジネス分析

  • 核酸医薬CDMOの地域別市場シェア、2022年および2030年
  • 北米
    • 北米核酸医薬CDMO市場、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の核酸医薬CDMO市場、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • アジア太平洋の核酸医薬CDMO市場、2018～2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの核酸医薬CDMO市場、2018～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA核酸医薬CDMO市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 企業の分類
  • 戦略マッピング
    • 合併と買収
    • コラボレーション
    • 新製品の発売
  • 参入企業の概要
    • Catalent
    • Thermo Fisher Scientific
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Cognate BioServices
    • Eurofins Genomics
    • Sirion Biotech
    • Oxford Biomedica
    • Danaher（Aldevron）
図表

List of Tables

  • Table 1 List of data sources
  • Table 2 Global Nucleic Acid Therapeutics CDMO Market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 4 Global Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 5 Global Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 6 Global Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 7 North America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 9 North America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 10 North America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 11 North America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 12 U.S. Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 16 Canada Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 20 Europe Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 21 Europe Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 22 Europe Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 23 Europe Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 24 Europe Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 25 UK Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 26 UK Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 27 UK Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 28 UK Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 29 Germany Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 33 France Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 34 France Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 35 France Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 36 France Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 37 Italy Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Italy Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 39 Italy Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 40 Italy Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 41 Spain Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 42 Spain Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 43 Spain Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 44 Sapin Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 45 Denmark Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 46 Denmark Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 47 Denmark Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 48 Denmark Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 49 Sweden Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 50 Sweden Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 51 Sweden Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 52 Sweden Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 53 Norway Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Norway Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 55 Norway Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 56 Norway Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 57 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 58 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 60 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 61 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 62 Japan Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Japan Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 64 Japan Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 65 Japan Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 66 China Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 67 China Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 68 China Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 69 China Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 70 India Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 71 India Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 72 India Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 73 India Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 74 South Korea Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 75 South Korea Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 76 South Korea Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 77 South Korea Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 78 Australia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Australia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 80 Australia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 81 Australia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 82 Thailand Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Thailand Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 84 Thailand Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 85 Thailand Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 86 Latin America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 87 Latin America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 88 Latin America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 89 Latin America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 90 Latin America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 91 Brazil Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 92 Brazil Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 93 Brazil Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 94 Brazil Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 95 Mexico Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 96 Mexico Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 97 Mexico Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 98 Mexico Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 99 Argentina Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 103 MEA Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 104 MEA Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 105 MEA Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 106 MEA Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 107 MEA Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 108 South Africa Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 112 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 116 UAE Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 120 Kuwait Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 124 Participant's overview
  • Table 125 Financial performance
  • Table 126 Type benchmarking
  • Table 127 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Nucleic Acid Therapeutics CDMO Market revenue, 2018-2030 (USD Billion)
  • Fig. 9 Nucleic Acid Therapeutics CDMO Market Snapshot
  • Fig. 10 Nucleic Acid Therapeutics CDMO Market driver impact
  • Fig. 11 Nucleic Acid Therapeutics CDMO Market Restraint Impact
  • Fig. 12 Porter's 5 Forces Analysis
  • Fig. 13 PESTEL Analysis
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO Market: Type Key Takeaways
  • Fig. 16 Global Gene Therapy Market, 2018 - 2030 (USD Billion)
  • Fig. 17 Global RNA-based Therapies Market, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO Market: Service Key Takeaways
  • Fig. 20 Global Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Others Market, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • Fig. 25 Global Nucleic Acid Therapeutics CDMO Market: End Users Key Takeaways
  • Fig. 26 Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 27 Government & Academic Research Institute Market, 2018 - 2030 (USD Billion)
  • Fig. 28 Biotech Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • Fig. 30 Global Nucleic Acid Therapeutics CDMO Market: Application Key Takeaways
  • Fig. 31 Oncology Market, 2018 - 2030 (USD Billion)
  • Fig. 32 Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • Fig. 33 Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • Fig. 34 Others Market, 2018 - 2030 (USD Billion)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 Regional Outlook, 2022 & 2030
  • Fig. 37 North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 38 U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 39 Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 41 Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 42 UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 43 France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 46 Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 48 Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 51 China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 52 India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 54 South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 55 Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 57 Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 59 Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 61 South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 63 UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 65 Market participant categorization
  • Fig. 66 Heat map analysis
目次
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is expected to reach USD 22.42 billion by 2030, advancing at a CAGR of 9.4% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2022. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies
  • In 2022, the manufacturing services segment dominated the market, accounting for over 38% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency
  • The biotechnology companies held a major revenue share of over 58% in 2022 due to substantial investments in the research and development of innovative therapies
  • By application, the oncology segment led the global market with a revenue share of over 31.0% in 2022. This is attributed to the rising adoption of gene therapy and RNA-based therapeutics and the increasing pipeline of nucleic acid therapeutics for oncology
  • North America held the largest revenue share of 38.49% in the nucleic acid therapeutic CDMO market in 2022. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • 4.2. Gene Therapy
    • 4.2.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
  • 4.3. RNA-based Therapies
    • 4.3.1. RNA-based Therapies Market, 2018 - 2030 (USD Billion)

Chapter 5. Service Business Analysis

  • 5.1. Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • 5.2. Process Development and Optimization
    • 5.2.1. Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • 5.3. Manufacturing Services
    • 5.3.1. Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • 5.4. Analytical and Quality Control Services
    • 5.4.1. Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. End Users Business Analysis

  • 6.1. Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • 6.2. Pharmaceutical Companies
    • 6.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • 6.3. Government & Academic Research Institutes
    • 6.3.1. Government & Academic Research Institutes Market, 2018 - 2030 (USD Billion)
  • 6.4. Biotech Companies
    • 6.4.1. Biotech Companies Market, 2018 - 2030 (USD Billion)

Chapter 7. Application Business Analysis

  • 7.1. Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 7.3. Genetic Disorders
    • 7.3.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Nucleic Acid Therapeutics CDMO Market Share by Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Framework
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Framework
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.8. Norway
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.9. Denmark
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Mergers & Acquisitions
    • 9.2.2. Collaborations
    • 9.2.3. New Product Launches
  • 9.3. Participant's overview
    • 9.3.1. Catalent
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Lonza
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. FUJIFILM Diosynth Biotechnologies
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Cognate BioServices
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Eurofins Genomics
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Sirion Biotech
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Oxford Biomedica
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Danaher (Aldevron)
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives